OptiBiotix Health plc Analyst briefing and investor presentation

OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol, diabetes and skin care, will announce its final results for the year ended 30 November 2016 on Tuesday, 25 April 2017.

Analyst briefing

A briefing for analysts only will take place at the offices of Walbrook PR, 4 Lombard St., London EC3V 9HD at 9.30am on Tuesday 25 April 2017.

Investor presentation

Stephen O’Hara will be giving a presentation for investors on the afternoon of Tuesday 25 April 2017 in the Grill room at the London Capital Club, 15 Abchurch Lane, London EC4N 7BW from 4.30pm for a 4.45pm start. The presentation will outline the Company’s strategy to deliver value for shareholders and give an update for the year. This will be followed by light refreshments and an opportunity to network.

If you would like to register to attend either briefing, or require further information, please contact Walbrook PR on 020 7933 8780 or email optibiotix@walbrookpr.com.

Click to view all articles for the EPIC: OPTI
Or click to view the full company profile:

How to attend Turner Pope Investments Investor Evening – Monday 13th May 2019

10th May 2019

Turner Pope Investments will be holding an Investor Evening this Monday 13th May 2019. With spaces limited it is important you reserve your spot via the email address at bottom. Venue:The Saloon, The Ned Hotel (www.thened.com), 27

NutraIngredients Awards shortlist announced

23rd March 2018

NutraIngredients is pleased to announce the shortlisted finalists for the 2018 edition of the NutraIngredients Awards … with the winners announced at our exclusive awards evening in Geneva on 16th May. The shortlisted finalistsfor the 10

OptiBiotix Health plc Launch of Slimbiome® in Nutri-bites®

8th March 2018

OptiBiotix Health plc (LON:OPTI), a life sciences business developing compounds to tackle obesity, and high cholesterol, today announced the launch of its award winning SlimBiome® in Nutri-Bites® with its US partner, Cereal Ingredients (“CII”), at the 2018 Natural

OptiBiotix Health PLC LPLDL® Exclusive European License Agreement

6th March 2018

OptiBiotix Health PLC (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol, diabetes and skin care, today announced that it has entered into a production and commercialisation agreement with Fine Foods &

OptiBiotix Health PLC OptiBiotix Capital Reorganisation

28th February 2018

OptiBiotix Health plc (LON:OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol, diabetes announced on 28 November 2017 that it intended to seek a cancellation of its share premium account (the “Capital Reduction”) in

Optibiotix Health PLC In a Strong Position

1st February 2018

Optibiotix Health PLC (LON:OPTI) Chief Executive Officer Stephen O’Hara talks to tells Proactive Investors about focussing on the commercialisation of their technology across the company’s platforms.

OptiBiotix Health plc “Results of further human taste studies” Stephen O’Hara, CEO

23rd January 2018

Stephen O’Hara, CEO of OptiBiotix LON:OPTI commented: “We are pleased with the results of this study which showed OptiBiotix’s sweet oligosaccharide had the highest sweetness and was low in off-flavours when compared to a wide range

OptiBiotix Health plc will be presenting at ProBiota 2018 in Barcelona from 7-9 February 2018

17th January 2018

OptiBiotix Health plc (AIM:OPTI), a life sciences business developing compounds to tackle obesity,high cholesterol, diabetes and skin care, announced this morning that it has had an abstract accepted for presentation at ProBiota 2018 in Barcelona from

Functional weight loss ingredient, SlimBiome brought to US

15th December 2017

OptiBiotix Health PLC (LON:OPTI), a specialist in the development of functional ingredients to modulate the human microbiome, has entered into a manufacturing and supply agreement with Cereal Ingredients. The agreement grants Cereal Ingredients a licence to

SlimBiome® – Supporting hunger-free weight management

14th December 2017

Slimbiome® is OptiBiotix’s patented combination of natural ingredients, identified and developed by leading experts in nutrition and metabolism, which supports scientifically substantiated weight loss claims. In independent tests the component ingredients have shown reductions in calorie intake

OptiBiotix Health plc SlimBiome® USA manufacturing, supply and profit sharing agreement

12th December 2017

OptiBiotix Health plc (LON:OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol, diabetes and skin care, announced today it has entered into a manufacturing and supply agreement with Cereal Ingredients, Inc, (“CII”). The agreement

Non-prescription lifestyle therapies may be key to reducing the nation’s blood pressure

6th December 2017

Optibiotix Health CEO Stephen O’Hara commented “High blood pressure and high cholesterol are significant risk factors in cardiovascular disease. Numerous scientific studies have shown that In combination these factors work together to greatly increase the risk of

OptiBiotix Health PLC Proposed Directorate Changes

5th December 2017

OptiBiotix Health PLC (LON:OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol, diabetes and skin care, today announced that subject to the completion of normal regulatory due diligence Neil Davidson CBE will be appointed as Non- Executive Chairman on 1 January 2018. Adam Reynolds, the current Non-Executive Chairman will

Optibiotix Health PLC on Kelloggs’ Sugar Levels Cut

30th November 2017

Following the announcement today from Kelloggs to cut the amount of sugar in its three top selling children’s cereals, we caught up with Stephen O’Hara, CEO of OptiBiotix Health PLC (LON:OPTI) for his thoughts: “We are really

OptiBiotix Health plc releasing value to shareholders with future further dividend payments

28th November 2017

OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol, diabetes and skin care, announces that it intends to convene a General Meeting to seek shareholder consent to undertake a

Optibiotix Win ‘Best Functional Ingredient for Health and Wellbeing’

23rd November 2017

Food Matters Live has announced the winners of its inaugural awards, which celebrate the incredible innovation that continues to shape the future of food and drink. These awards recognize the creativity and inventiveness of industry to

OptiBiotix Health plc “updates investors on the significant progress” says Stephen O’Hara, CEO

8th November 2017

OptiBiotix Health plc (LON:OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol, diabetes and skin care gave DirectorsTalk the following product development and commercial update on its SlimBiome(R) product platform. Stephen O’Hara, CEO

OptiBiotix Health plc gives world leading Knighton Foods a manufacturing and supply agreement

1st November 2017

Be sure to check our sister interview main ratings news website